COX-2 inhibitors and cardiovascular risk

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Translational Research

Background:

• Selective cyclooxygenase-2 (COX-2) inhibitors were developed based on cellular knowledge.
• Concerns about prothrombotic effects and cardiovascular risks led to market withdrawal of some COX-2 inhibitors.
• Both selective and non-selective COX inhibitors are linked to increased blood pressure.

Purpose of the Study:

• To investigate the cardiovascular risks associated with COX-2 inhibitors.
• To explore whether cardiovascular risks are a class effect or dependent on COX-2 selectivity.
• To provide recommendations for managing patients on COX-inhibitors.

Main Methods:

• Review of existing research on COX-inhibitors and cardiovascular events.
• Analysis of the relationship between COX-inhibitor use, blood pressure, and cardiovascular risk.
• Hypothetical reasoning based on observed data.

Main Results:

• COX-inhibitors, including selective COX-2 inhibitors, are associated with increased blood pressure.
• Elevated blood pressure, even minor, significantly increases cardiovascular morbidity risk in susceptible individuals.
• The cardiovascular risks observed with rofecoxib and valdecoxib may not be generalizable to all COX-2 inhibitors.

Conclusions:

• The cardiovascular adverse effects of COX-inhibitors may be primarily due to increased blood pressure in high-risk populations.
• Prudent management includes monitoring blood pressure, considering low-dose aspirin, and using antihypertensive medications.
• Dietary salt restriction may help mitigate blood pressure effects.